Related Experiment Video

Updated: Mar 15, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.8K

Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies

Maurie Markman1

  • 1Cancer Treatment Centers of America, Philadelphia, PA, USA Drexel University College of Medicine, Philadelphia, PA, USA maurie.markman@ctca-hope.com.

Women'S Health (London, England)
|September 18, 2016
PubMed

Insights

This commentary discusses rational endpoints for clinical trials of new anti-neoplastic agents in gynecologic cancers. The author suggests conclusions will vary for ovarian, cervical, and endometrial cancers.

Area of Science:

  • Oncology
  • Gynecologic Oncology
  • Clinical Trial Design

Background:

  • Regulatory approval for anti-neoplastic agents requires robust clinical trial data.
  • Gynecologic malignancies include ovarian, cervical, and endometrial cancers.
  • Defining appropriate endpoints is crucial for trial success and drug approval.

Purpose of the Study:

  • To discuss the concept of rational endpoints in clinical trials for new anti-neoplastic drugs.
  • To explore the specific application of these endpoints in gynecologic cancers.
  • To postulate differing conclusions for individual gynecologic malignancies.

Main Methods:

  • Literature review and expert commentary.
  • Analysis of clinical trial endpoint strategies.
  • Comparative discussion across gynecologic cancer types.

Main Results:

  • The selection of rational endpoints is critical for anti-neoplastic drug development.
  • Standardized endpoints may not be universally applicable across all gynecologic cancers.
  • Ovarian, cervical, and endometrial cancers may necessitate distinct endpoint considerations.

Conclusions:

  • Rational endpoints in clinical trials are essential for regulatory approval of anti-neoplastic agents.
  • The optimal endpoints for gynecologic malignancies are likely to differ between ovarian, cervical, and endometrial cancers.
  • Further discussion is warranted to refine endpoint selection for these specific cancers.
Keywords:
cervical cancerchemotherapy of gynecologic cancerscisplatinendometrial cancergynecologic cancersovarian cancerrandomized trials

More Related Videos

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.8K

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
519
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.3K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
811
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.1K